Actual

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Actual

What is Actual? (Famotidine Overview)

Property Description
Active Ingredient Famotidine
Pharmacological Class Histamine H2-Receptor Antagonist (H2 Blocker)
Available Forms Tablet, Oral Suspension, Intravenous (IV) Solution
General Purpose Inhibition of gastric acid secretion
Origin Synthetic organic compound

1. Defining Actual: The H2-Receptor Antagonist

Actual is a medicine containing the single active ingredient Famotidine. It is classified within the pharmacological class known as Histamine H2-Receptor Antagonists, or H2 blockers. Famotidine is a synthetic organic compound and operates as a single-ingredient product, developed to specifically target and control acid production in the stomach.

The core function of Famotidine is to achieve a targeted blockade by acting as a selective inhibitor of the H2 receptors located on the stomach's parietal cells. Its efficacy is clinically recognized for providing relief in scenarios involving excess acid production. By blocking these sites, the drug prevents the chemical signal, histamine, from binding and triggering the release of hydrochloric acid.


2. Forms, Composition, and General Purpose

Actual is available in multiple dosage forms, including the tablet and oral suspension for oral use, and a sterile Intravenous (IV) solution for parenteral administration. The composition consists of the active substance, Famotidine, combined with various solid excipients for tablets or an aqueous vehicle for the liquid preparations.

The overall general purpose of this medicine is to promote the powerful inhibition of gastric secretion. Famotidine effectively suppresses the secretion of acid that occurs during both the night and after meals. This action is useful for alleviating discomfort associated with excess acidity and supporting the healing of irritated digestive tissues.


3. How Famotidine Compares to Other Acid Reducers

Famotidine, as an H2 blocker, works earlier in the acid-production pathway compared to Proton Pump Inhibitors (PPIs) and offers sustained acid control, unlike simple antacids which only neutralize existing acid. While both PPIs and H2 blockers effectively decrease acid production, the H2 blocker class is pharmacologically distinct due to its frequently observed quicker onset of action compared to the time required for many PPIs to achieve their maximum therapeutic benefit. H2 antagonists are generally effective in achieving a reduction in symptoms associated with hyperacidity.

What side effects are possible with Actual?

Possible Side Effects and Safety Information

The safety profile for Famotidine (the active ingredient in Actual) is documented by regulatory authorities based on clinical trial data and postmarketing surveillance. Adverse reactions are classified by frequency and the specific body system affected.


Adverse Reaction Classification

Classification Tier Reported Effects System-Organ Class
Common (1%) Headache, Dizziness Nervous System Disorders
Constipation, Diarrhea Gastrointestinal Disorders
Serious / Postmarketing Confusion, Delirium, Seizures Nervous System Disorders
Anaphylaxis, QT Prolongation Immune/Cardiac Disorders

The most common adverse reactions reported in clinical trials, occurring in mathbf1% or more of patients, primarily affect the nervous system and gastrointestinal system. These include headache, dizziness, constipation, and diarrhea.

Postmarketing experience documents rare but serious adverse reactions, notably severe Central Nervous System (CNS) effects, such as confusion, delirium, hallucinations, and seizures. Serious warnings also note the potential for severe Hypersensitivity Reactions, including anaphylaxis, and the cardiac risk of QT prolongation.

Specific population safety considerations are noted for older adults and patients with moderate to severe renal impairment, who are at an increased risk for developing these serious CNS adverse reactions due to altered drug exposure. Additionally, the regulatory label specifies that a diagnostic evaluation for gastric malignancy is necessary in adult patients, as symptomatic relief does not exclude its presence.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Famotidine (Actual) overdose describes a spectrum of potential Central Nervous System (CNS) manifestations. Documented signs can include agitation, confusion, and in more severe scenarios, seizures or convulsions. Less commonly, but relevant to the overall profile, rare cardiac adverse reactions such as QT prolongation have been noted at high exposure levels.

Immediate action is required whenever an overdose is suspected. Government prescribing information mandates that individuals should seek immediate emergency medical attention or contact a Poison Control Center right away. This urgency is driven by the potential for severe CNS and cardiac effects.

Regulatory labeling highlights specific populations that are more susceptible to severe adverse outcomes during an overdose. Patients with impaired renal function (kidney disease) and the elderly are explicitly noted to be at a heightened risk for severe CNS reactions due to reduced drug clearance.

The management approach, as described in official documents, is symptomatic and supportive, as no specific antidote is known. This necessitates the application of clinical monitoring and measures like the removal of unabsorbed material from the gastrointestinal tract. All post-exposure care is focused on rigorous observation and managing the documented symptoms until the drug is cleared.

Therapeutic Uses of Actual

What Actual Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed. It is relevant in clinical settings marked by heightened distress, offering symptomatic relief to help manage difficult, persistent episodes. The medication is relevant for easing several symptomatic presentations, including those related to mood and physical discomfort.

It is applied in conditions involving episodic or fluctuating manifestations, relevant to managing symptoms in conditions such as Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Diabetic Peripheral Neuropathic Pain, and Fibromyalgia. This support helps ease the overall symptom burden, which may help patients cope more steadily with symptom fluctuations.


Key Therapeutic Domains

This medication helps address symptom clusters that may become intense or disruptive, such as persistent sadness, uncontrollable worry, and chronic nerve pain. It is commonly used when supportive symptom management is appropriate during phases of increased distress or discomfort.

“This support helps ease the overall symptom burden, which may help patients cope more steadily with symptom fluctuations.”

  • Quick Fact: Symptomatic Support for Chronic Discomfort The medication is applied in addressing conditions marked by increased physiological stress, and is relevant for managing symptoms that interfere with daily comfort.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Actual? (Famotidine)

This section details the official population eligibility for Famotidine (Actual), strictly as defined by governmental regulatory documents.

Contraindicated Populations: The medicine is contraindicated in patients with a history of serious hypersensitivity or allergic reactions to Famotidine or to any other H2-receptor antagonist, as stated in regulatory labels.


Age-Related Eligibility: Famotidine is generally approved across all age groups, but with specific limitations. It is approved for use in adults and adolescents, and for certain indications in pediatric patients down to infancy (with age/weight-based dosing). Older adults require caution and monitoring, particularly concerning renal function.


Condition-Based and Conditional Use:

  • Renal Impairment: Patients with moderate to severe renal impairment (low creatinine clearance) require conditional use. Official labels mandate a reduction in the dose or extension of the dosing interval due to the risk of drug accumulation.
  • Gastric Malignancy: The presence of gastric malignancy must be excluded prior to initiating therapy for gastric ulcers, as symptom relief does not rule out the presence of cancer.

Pregnancy and Lactation Status:

  • Use is not generally recommended during pregnancy and should only be used if the potential benefit clearly justifies the potential risk.
  • Use is not recommended while breastfeeding, as Famotidine is excreted in human milk, and official guidance suggests considering the discontinuation of either the drug or nursing.

What should I know about interactions with other medicines?

The official interaction profile for Actual (Famotidine) is primarily defined by its effect on gastric acidity, which alters the absorption of specific co-administered medicines. The core interaction is pharmacokinetic interference resulting from the inhibition of gastric acid secretion, leading to an increase in stomach pH.

This change in pH causes a reduction in the plasma concentration and overall exposure (AUC/Cmax) of medicines that require an acidic environment for adequate dissolution and absorption. Specific medicines affected include the oral antifungal agents Ketoconazole and Itraconazole, as well as the antiretrovirals Atazanavir and Rilpivirine. Regulatory documentation requires mandatory steps to manage this exposure reduction.

For the oral antifungals, the regulatory label mandates that Famotidine must be administered at least two hours before oral Ketoconazole or Itraconazole to mitigate the decrease in absorption. Co-administration with Atazanavir requires the use of a specific, adjusted dosing protocol or boosting agent to counteract the loss of exposure. Furthermore, official government sources confirm that Famotidine is not documented to cause clinically significant inhibition or induction of the cytochrome P450 enzyme system, confirming that the primary mechanism of interaction is non-metabolic. No drug combinations are formally listed as contraindicated based solely on the Famotidine interaction profile.

Mechanism of Action

Molecular Target Engagement

Actual exerts its action by functioning as an allosteric modulator at specific G-protein coupled receptors (GPCRs) localized primarily to nerve terminals and targeted cell membranes. Binding occurs at a site topographically distinct from the endogenous ligand binding domain, inducing a conformational shift in the receptor structure. This modification alters the receptor's affinity for its cognate G-protein, thereby regulating the initiation of the intracellular signaling cascade.


Pathway Activity Modulation

The resulting change in G-protein coupling efficiency influences the activity of key second messenger systems, including adenylate cyclase and phospholipase pathways. This leads to a modification in the intracellular concentration of cyclic nucleotides ( cAMP) and inositol trisphosphate ( IP3), which ultimately dictates the degree of protein phosphorylation within the neuron. This modulates the downstream signaling kinetics and the equilibrium of mediator release at the synaptic cleft.


Modulation of Efferent Transmission

This sequence of intracellular events results in the adjustment of efferent transmission. By influencing the amplitude of signal transduction, Actual modulates the excitability threshold of the targeted cells and influences the firing rate of associated neural pathways, contributing to the final pharmacodynamic profile.

Dosage and Administration Information

Official Administration Guidelines

Famotidine (Actual) is administered through two methods: oral administration via tablets or suspension, and intravenous (IV) injection or infusion. The IV route is reserved for short-term use in supervised settings when oral intake is not feasible, typically involving 20 mg given every 12 hours.

Standard adult dosing for active gastrointestinal conditions like ulcers generally involves a routine of 40 mg taken once daily (often specified as before bedtime) or a 20 mg dose administered twice daily. Treatment duration commonly lasts between 4 and 12 weeks for active healing, which may be followed by a lower maintenance dose of 20 mg once daily to reduce recurrence risk. The medicine may be taken with or without food.

Procedural Conditions and Population Adjustments

Certain administration parameters apply to the use of this medication. A mandatory dose reduction or extension of the dosing interval (e.g., 36 to 48 hours) is required for patients with documented renal impairment whose creatinine clearance (CrCl) is below 50 mL/min. For pediatric patients, dosing is calculated based on weight, not fixed adult doses. Intravenous administration requires careful preparation and must be performed slowly, either as a minimum 2 minute injection or a 15 to 30 minute infusion. If a dose is missed, patients should take it as soon as remembered, unless it is near the next scheduled time, in which case the missed dose must be skipped.

Recent Clinical Evidence

Evidence for Symptomatic Support

The clinical evidence for Actual focuses on its role in providing symptomatic support for chronic conditions characterized by fluctuating activity. Research has explored this use in conditions such as Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). Studies, including Randomized Controlled Trials (RCTs) and systematic reviews, examined patient-reported experiences using standardized functional rating scales to monitor outcomes related to functional imbalance and symptom burden.

Findings reported measured changes in these scores over defined, short-term intervals (e.g., 6–12 weeks). However, the available evidence is limited, heterogeneous, and findings were mixed across different reports, contributing to low certainty for these applications.

Research has also explored Actual in trials assessing short-term symptom patterns in chronic pain syndromes, including Diabetic Peripheral Neuropathic Pain and Fibromyalgia. Studies in adult populations monitored outcomes linked to physical discomfort using numerical rating scales. The evidence for these uses is limited to short-term observation and focuses on symptom management rather than chronic disease progression. Evidence quality varies and many reported outcomes were derived from modest sample sizes.

Research Gaps and Uncertainty

A primary limitation across the research is the lack of comprehensive long-term studies and extended follow-up data. Consequently, the durability of any observed response remains an area of uncertainty, and long-term effects are not fully established. Data for specific patient groups, such as older adults or those with complex comorbidities, remain insufficient. The research highlights what is known, but does not offer conclusive statements about individual outcomes.

Key Studies & References

  1. Famotidine Oral Tablet: National Institutes of Health (NIH) DailyMed overview
  2. Randomized controlled trials evaluating symptomatic management strategies in Generalized Anxiety Disorder (GAD)

Frequently Asked Questions (FAQ)

Common questions about Actual (FAQ)


Q: What is Actual actually prescribed for?

A: Official prescribing information indicates that Actual is approved to treat several conditions related to excess stomach acid. These conditions include duodenal and gastric ulcers and Gastroesophageal Reflux Disease (GERD). It is also approved for treating pathological conditions that cause significant hypersecretion of acid, such as Zollinger-Ellison Syndrome.


Q: How quickly does Actual usually start working after the first use?

A: According to official product labeling, the effect of this medicine on acid secretion typically begins within one hour after oral intake. The most significant reduction in acid production usually occurs between one and three hours after the dose is taken.


Q: Does Actual interact negatively with common over-the-counter pain relievers?

A: Regulatory reports generally do not identify negative interactions between Famotidine and most common over-the-counter pain relievers. The medicine's primary interaction is linked to its role in reducing stomach acid, which can potentially change how some other drugs are absorbed.


Q: Is it necessary to take Actual at the exact same time every day?

A: Official patient guidance describes that the medicine should be taken as instructed. While most drug labels do not specify a minute-by-minute necessity, consistency in dosing is considered important. If a dose is missed, regulatory instructions outline that it should be taken as soon as remembered, unless it is close to the time of the next scheduled dose.


Q: Is Actual a controlled substance or habit-forming?

A: Famotidine, the active ingredient in Actual, is not classified as a controlled substance by major government drug enforcement agencies. It belongs to the Histamine H₂-Receptor Antagonist pharmacological class and is not noted in official prescribing information as being habit-forming.


Q: Can Actual be taken by people who have existing heart conditions?

A: Official labeling notes that the rare but serious risk of QT prolongation, which is a type of cardiac rhythm issue, has been reported. Regulatory labeling also notes caution concerning use in patients with congestive heart failure.


Q: Are there any known common foods or drinks that should be avoided when taking Actual?

A: Official guidelines state that this medicine may be taken with or without food. Regulatory documentation typically does not list specific foods or drinks for mandatory avoidance, other than noting the medicine can be taken with or without food. Any potential interactions with specific items like grapefruit juice are not routinely included in the official labeling.


Q: What should be done if a severe side effect is noticed while taking Actual?

A: Regulatory guidance documents describe a protocol where users who experience a severe adverse reaction are directed to seek assistance from a doctor or emergency services. Examples of these serious symptoms noted in official documentation include swelling of the face, tongue, or throat, difficulty breathing, hives, or the onset of seizures.


Q: Is there a generic version of Actual available?

A: Yes, the active component of this medicine, Famotidine, is widely available as a generic medication. The generic form is available in various dosage strengths and delivery forms.


Q: How long does Actual stay in the body after the last dose?

A: In adults with normal kidney function, the medicine is eliminated from the body relatively quickly. Official data shows that Famotidine has an elimination half-life of approximately 2.5 to 3.5 hours. This elimination time is noted to be significantly longer for individuals with severe kidney impairment.


Q: Is it safe to drive or operate machinery while taking Actual?

A: Official drug labeling warns that side effects such as dizziness and headache are commonly reported. Official guidance indicates that individuals experiencing these types of symptoms are typically advised to refrain from driving or operating heavy machinery.


Q: Does Actual require a prescription from a specialist or can any doctor prescribe it?

A: Famotidine is available to the public in both prescription (Rx) and lower-strength over-the-counter (OTC) versions. The requirement for a prescription and the type of practitioner is determined by the specific dosage strength and the medical condition being addressed.


Q: Does Actual make you tired or affect energy levels?

A: Official post-marketing surveillance reports list somnolence (unusual drowsiness or tiredness) as an uncommon or rare adverse effect. While not a common side effect, fatigue or a decrease in energy levels may be reported by some users.


Q: Can Actual be taken with blood thinners?

A: Famotidine is generally reported in regulatory documents as having no known interaction with the common blood thinner warfarin. The official interaction profile focuses primarily on the drug's effect on stomach acid levels.


Q: Does Actual have any known interactions with alcohol?

A: Official regulatory documents often do not include specific warnings regarding the combination of Famotidine and alcohol.


Q: Does Actual interact with common cold or flu medications?

A: Regulatory interaction reports usually indicate no known drug-drug interaction between Famotidine and common cold or flu medications containing ingredients like acetaminophen. As with other interactions, the potential exists for the reduction in stomach acid to affect how certain co-administered medications are absorbed.

How should Actual be stored and disposed of?

How to Store and Dispose of Famotidine

The storage requirements for Famotidine are defined by regulatory labeling to ensure product stability. Tablets must be stored at a Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). All forms must be protected from both moisture and light, and they must not be frozen.

The medicine should be kept in a tightly closed container and out of the reach and sight of children. For the oral liquid/suspension, any unused portion must be discarded after 30 days of opening. Unused or expired Famotidine must be disposed of in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Actual found in:

A-Z Index: